Promega Secures NMPA Approval for MSI Detection Kit as KEYTRUDA Companion Diagnostic in China
Event summary
- China's NMPA approved Promega's OncoMate® MSI Detection Kit as a Class III in vitro diagnostic medical device.
- The kit is intended for use as a companion diagnostic to identify MSI-High (MSI-H) solid tumor patients for treatment with KEYTRUDA®.
- This marks the first Promega companion diagnostic approved by the NMPA.
- The approval was supported through collaboration with Merck & Co., Inc., the marketer of KEYTRUDA.
The big picture
This approval underscores the growing importance of companion diagnostics in precision oncology, particularly in high-burden markets like China. The collaboration with Merck highlights a strategic alignment between diagnostic and therapeutic companies to improve cancer treatment outcomes. With solid tumors representing the majority of cancer diagnoses in China, this approval could significantly impact treatment strategies for advanced solid tumor patients.
What we're watching
- Market Expansion
- How Promega will leverage this approval to expand its presence in China's oncology diagnostics market.
- Commercialization Pace
- The pace at which the OncoMate® MSI Detection Kit becomes available for purchase in China.
- Regulatory Synergies
- Whether this approval will accelerate regulatory approvals for other companion diagnostics in China.
Our editorial coverage:
Related topics